Latest Headlines

Latest Headlines

Catalent targets South Korea with CTC Bio partnership

Catalent Pharma Solutions has teamed up with South Korea's CTC Bio to attract clients looking to market solid oral dose and controlled-release products in the U.S. and Europe.

Pfizer launches joint venture with Chinese API maker

Pfizer has launched a joint venture with China's Zhejiang Hisun Pharmaceuticals, a contract API manufacturer, planning to develop, manufacture and commercialize off-patent pharmaceutical products in China.

Patheon lifts profit outlook after strong quarter

Global CMO Patheon reported a 115% increase in gross profit in its fiscal third quarter, after suffering a $20.9 million quarterly operating loss in March.

CMO Patheon sells off clinical packaging biz

Global CMO Patheon sold its secondary clinical packaging and clinical distribution services business, part of the company's ongoing efforts to slash costs and reposition itself.

FDA slaps DPT with warning letter over sterility concerns

The FDA found sterility issues at DPT Laboratories' Center of Excellence for Sterile and Specialty Products, and the agency said DPT hasn't done enough to prevent future problems.

Hospira drops $200M on Indian API plant

Looking to cut costs, Hospira is practicing some vertical integration, spending $200 million on an Indian API-producing plant run by Orchid Chemicals & Pharmaceuticals.

Charles River snaps up Accugenix for $17M

Charles River Labs spent $17 million to acquire Accugenix, a provider of contract microbial testing, looking to bolster its own detection portfolio.

Catalent sues United Drug over alleged breach of trust

During a conference call with analysts last year, United Drug's CEO disclosed that Catalent was selling its packaging business. Fast-forward a year later and Catalent has filed a lawsuit, saying the disclosure was a breach of confidentiality.

West to open CMO facility in India

Despite its plans to move away from contract manufacturing and boost its proprietary products, West Pharmaceutical is building an injectables plant in Sri City, India.

Pfizer backs out of generics deal with India's Claris

Just as India's Claris Lifesciences got out from under a two-year FDA ban, Pfizer ($PFE) nixed its supply deal with the company and will no longer sell generic injectables manufactured by the drugmaker.